New POLARIS Phase I/II data presented at ASGCT show ETX101 gene therapy reducing seizures and improving neurodevelopment in children with SCN1A+ Dravet syndrome.

Researchers mapped more than 100 mutations that allow diverse HIV-1 strains to evade broadly neutralizing antibodies.

Built around the packages Sprint, Flex, and Flex+, Gene Synthesis 2.0 introduces a streamlined, intuitive ordering experience ...

EnGene (NASDAQ: ENGN) stock suffered a more-than-80% plunge this past week that reflects just how competitive the field is ...

There is no margin for error in the pharma and biopharma sectors. If the chain-identity breaks anywhere along the way, there ...

At ASGCT, the company will share data showing that its RNA achieves higher, more durable protein expression compared to other ...

The FDA has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni™ (lunsotogene parvec-cwha) as the first gene ...

Enein, MD, PhD, for a measurement-driven approach that advances cell therapy translation, from high-dimensional analytics to ...

Macrophages use cell‑volume changes to sense danger, reprogram gene expression, and heighten inflammatory and antiviral ...

Researchers say identified mAbs could represent “a basis to develop a treatment that is urgently needed as measles virus ...

Bayer has agreed to acquire Perfuse Therapeutics for up to $2.45 billion, in a deal designed to broaden the buyer’s ophthalmology pipeline with Perfuse’s sole pipeline drug and two clinical phase ...

A pair of recently-released studies shed new light on the staggering cost of developing new drugs—an expense that now exceeds $2 billion per therapy on average. In one report, business services ...